Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study of intracerebroventricular administration of GC1123 for the treatment of neurocognitive decline associated with Hunter syndrome

Next Previous
Search
Trial Profile

A phase I/II study of intracerebroventricular administration of GC1123 for the treatment of neurocognitive decline associated with Hunter syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idursulfase (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 01 Nov 2021 According to a GC Pharma media release, the European Medicines Agency (EMA) granted orphan drug designation (ODD) to Hunterase ICV based on data from this trial.
  • 22 Jan 2021 Results presented in a GC Pharma media release.
  • 22 Jan 2021 Status changed from recruiting to completed, according to a GC Pharma media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top